Closed · RFA-FD-13-013 · CFDA 93.103 · Discretionary

Systematic Evaluation of Excipient Effects on the Efficacy of Metered Dose Inhaler Products (U01)

Federal grant opportunity posted by Food and Drug Administration, cataloged on Grants.gov.

$500K-$500K
Award range
Closed
Status
July 1, 2013
Close date
7
Expected awards

The verdict

Systematic Evaluation of Excipient Effects on the Efficacy of Metered Dose Inhaler Products (U01) is a closed discretionary listing from Food and Drug Administration that offered $500,000 -- $500,000 across 7 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 481 other opportunities from Food and Drug Administration.

$500K-$500K
award range
Closed
application status
7
expected awards
93.103
CFDA program

Archived opportunity record

Systematic Evaluation of Excipient Effects on… is closed (last close July 1, 2013). The parent program page for CFDA 93.103 is the reliable place to catch re-announcements. Food and Drug Administration still indexes 481 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed July 1, 2013

Posted May 7 Closes Jul 1

Est. Total Funding

$500,000

Expected Awards

7

Instrument

Cooperative Agreement

Description

There are a multitude of factors to be considered when developing a metered dose inhaler (MDI); drug-excipient interactions are one of them. Although much is known about these complex interactions at the empirical level, there is a lack of a systematic understanding of the effects of these interactions on the MDI product performance. More importantly, it is not well understood to what extent MDI product performance depends on the amount of co-solvents and surface active agents used in the formulation. Hence, a study that establishes this relationship would be very valuable, not only because it will provide a missing piece of scientific information in this area, but also because it will enhance the FDA's reviewing process under the quality by design (QbD) paradigm. Objectives The project will investigate the effect of excipient concentrations on the aerosolization performance of typical hydroflouroalkane (HFA)-based metered dose inhaler formulations and evaluate the sensitivity of the in vitro methods in detecting excipient concentration changes. Detailed Description The study will be divided into four phases. Phase 1: Selection of ideal drug candidates, representative drug particle sizes and design space of the study. Selection of ideal drug candidates: Selection of drug candidates should be based on their physicochemical properties, such that their results could be generalizable to other drugs. Additionally, the drug candidates should represent both solution and suspension MDIs. Selection of initial drug particle size to study suspension MDI: The drug candidates representing suspension MDIs, should be processed (micronized) to obtain two distinct particle size distributions that bracket the range of particle size distributions of the marketed formulations. Phase 2: Study the effect of addition of different amounts of co-solvent (ethanol) and surfactant (oleic acid) and propellant (HFA-134a) on MDI performance The effect of varying amounts of these three excipients on MDI performance should be evaluated. An appropriate experimental design (i.e. full/fraction factorial design, central composite design, or Box-Behnken design) should be selected to keep the number of experiments practically manageable without compromising the study power. The levels of excipients investigated in the study should be based on the inactive ingredient database (IID) safety limit. The study should include the scenarios where amounts of excipients are changed within as well as outside FDA's recommended Q2 acceptance limit of 5%. MDI performance should be tested using the Compendial tests (According to the methods described in USP and/or FDA's Guidance for Industry) and non-compendial tests including, but not limited to, dissolution and predictive total lung deposition using physical airway models. Phase 3: Study of other surfactants The knowledge and experience gained from the Phase 2 studies will be applied to evaluate other surfactants, such as povidone, lecithin NF, and sorbitan trioleate. Each surfactant should be evaluated at different levels; the levels defined based on individual IID safety limits and literature information. Phase 4: Mathematical modeling and overall recommendations Using the results obtained from this study, mathematical model(s) should be developed that can help predict the effect of change in excipient(s) amount on the in vitro performance of MDIs.

Wide-open applicant board · 14 Grants.gov doors

Systematic Evaluation of Excipient Effects on… prints 14 distinct Grants.gov eligibility doors (State governments; County governments; City or township governments; Special district governments; +10 more). Filter fit before reading award size as demand — most applicant classes appear on the row. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Health · Science and Technology / R&D (HL;ST). Only 8 other Food and Drug Administration listings share this exact eligibility-code string (2% of 482).

Code 00
State governments
Code 01
County governments
Code 02
City or township governments
Code 04
Special district governments
Code 06
Public / state-controlled institutions of higher education
Code 07
Federally recognized tribal governments
Code 08
Public / Indian housing authorities
Code 11
Native American tribal organizations (other than Federally recognized tribal governments)
Code 12
Nonprofits with 501(c)(3) status (other than IHEs)
Code 13
Nonprofits without 501(c)(3) status (other than IHEs)
Code 20
Private institutions of higher education
Code 22
For-profit organizations other than small businesses
Code 23
Small businesses
Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

Gladys Melendez-Bohler Grants Management Officer/Specialist Phone 301-827-7175

What to do next

Systematic Evaluation of Excipient Effects on… is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.103 may publish future NOFOs under the same assistance listing. Open program
  • Food and Drug Administration Research indexes 42 Grants.gov listings in this extract. Program profile
  • Food and Drug Administration lists 481 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants